moxifloxacin has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abousoud, O; Dagli, M; Gade, T; Hunt, S; Mondschein, J; Nadolski, GJ; Parikh, RS; Shamimi-Noori, S; Soulen, MC; Stavropoulos, SW; Sudheendra, D | 1 |
| Guo, Y; Hu, Y; Huang, Y; Liu, D; Lu, B; Wang, X; Zhu, Z | 1 |
2 other study(ies) available for moxifloxacin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Infection Rates Following Hepatic Embolotherapy in Patients with Prior Biliary Interventions: Comparison of Single-Drug Moxifloxacin and Multidrug Antibiotic Prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biliary Tract Surgical Procedures; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Therapy, Combination; Female; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Moxifloxacin; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2.
Topics: Adaptor Proteins, Signal Transducing; Annexin A2; Anti-Bacterial Agents; Antineoplastic Agents; Azithromycin; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoroquinolones; Gemcitabine; Humans; Liver Neoplasms; Mitoxantrone; Moxifloxacin; Mycoplasma hyorhinis; Protein Binding; Real-Time Polymerase Chain Reaction | 2017 |